After years of preparation, Eli Lilly is on the brink of launching ... head of connected care for Lilly Diabetes. "Using the learnings from early adopters of Tempo, we look forward to continually ...

Shares in Hims Hers Health Inc (NYSE:HIMS) soared over 40% on Tuesday after the telehealth group announced a "long-term collaboration" with Novo Nordisk A/S (NYSE:NVO) to offer the Danish firm’s ...

Eli Lilly is just weeks away from launching ... News of the impending GB launch has been welcomed by patient organisation Diabetes UK, whose head of care, Douglas Twenefour, said: “Supporting ...

After the FDA declared a semaglutide shortage in 2022, pharmacies, telehealth companies and other health care providers ... in Eli Lilly’s weight loss drug Zepbound and diabetes medication ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Yes, you can buy Zepbound online, but you’ll need a valid prescription from a healthcare professional, such as your primary care physician ... by insurance. Eli Lilly, the manufacturer of ...

Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds ...

Pharmaceutical company Eli Lilly announced promising clinical trial results this week for a daily pill to treat obesity and diabetes. Besides the good news of minimal side effects and impressive ...

Eli Lilly (NYSE ... Administration for obesity in late 2025 and diabetes in 2026, reflecting confidence in the drug's approval and rapid adoption. Lilly is already stocking $550 million in pre ...